Sean Duffy Sells 12,944 Shares of Omada Health (NASDAQ:OMDA) Stock

Omada Health, Inc. (NASDAQ:OMDA) CEO Sean Duffy sold 12,944 shares of Omada Health stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $20.40, for a total value of $264,057.60. Following the transaction, the chief executive officer directly owned 411,861 shares of the company’s stock, valued at $8,401,964.40. The trade was a 3.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Omada Health Stock Up 2.3%

Shares of OMDA opened at $19.54 on Friday. Omada Health, Inc. has a twelve month low of $10.28 and a twelve month high of $26.92. The stock has a market cap of $1.16 billion, a PE ratio of -72.37 and a beta of 1.73. The business’s 50-day moving average price is $20.24 and its 200-day moving average price is $16.15.

Omada Health (NASDAQ:OMDA) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.10. Omada Health had a negative net margin of 2.22% and a negative return on equity of 1.82%. Analysts expect that Omada Health, Inc. will post -0.01 earnings per share for the current fiscal year.

Key Headlines Impacting Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Quarterly results beat expectations. Omada reported adjusted earnings of $0.15 per share, up from a $0.09 loss a year earlier and above the $0.05 consensus estimate. Another earnings summary reported EPS of $0.08 versus an expected loss of $0.02, reinforcing that results exceeded forecasts. Omada Health Q2 earnings and revenues top estimates
• Positive Sentiment: Growth remained strong. Second-quarter revenue rose 43% year over year, while total members increased 45%. Gross margin also reached a new quarterly record, supporting the company’s growth and profitability narrative. Omada Health reports second-quarter 2026 results
• Positive Sentiment: Full-year revenue guidance exceeded Wall Street expectations. Omada forecast fiscal 2026 revenue of $334 million to $340 million, above the $327.2 million analyst consensus. This suggests management expects sustained demand for its digital chronic-care programs.
• Neutral Sentiment: Leadership transition adds an execution consideration. Co-founder and CEO Sean Duffy will become executive chair on January 1, 2027, while President Wei-Li Shao becomes CEO. The planned, internal succession may provide continuity, although investors will monitor whether the change affects growth execution.
• Negative Sentiment: CEO insider selling provided a modest counterpoint. Duffy sold 12,944 shares for approximately $264,000, reducing his direct ownership by 3.05%. While the sale may have been for personal or financial-planning reasons, insider selling can weigh on sentiment.

Hedge Funds Weigh In On Omada Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new position in Omada Health during the 2nd quarter worth approximately $32,000. Bellevue Group AG increased its stake in Omada Health by 0.7% in the 3rd quarter. Bellevue Group AG now owns 251,791 shares of the company’s stock worth $5,567,000 after purchasing an additional 1,791 shares during the period. Quarry LP bought a new stake in Omada Health in the fourth quarter valued at approximately $29,000. Barclays PLC lifted its position in Omada Health by 14.6% in the fourth quarter. Barclays PLC now owns 14,850 shares of the company’s stock valued at $234,000 after purchasing an additional 1,888 shares during the last quarter. Finally, TD Waterhouse Canada Inc. purchased a new stake in shares of Omada Health during the fourth quarter valued at approximately $32,000.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on OMDA shares. Wall Street Zen cut shares of Omada Health from a “buy” rating to a “hold” rating in a report on Saturday, July 18th. The Goldman Sachs Group restated a “buy” rating on shares of Omada Health in a research report on Friday, May 8th. Morgan Stanley restated an “overweight” rating and issued a $30.00 target price on shares of Omada Health in a research note on Monday, June 22nd. Wells Fargo & Company raised their price target on Omada Health from $17.00 to $18.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Finally, Weiss Ratings downgraded Omada Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, July 13th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $24.75.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.